about
Screening for peripheral arterial diseasePersonalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling studySex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort studySeparate prediction of intracerebral hemorrhage and ischemic strokeThe Quantitative Science of Evaluating Imaging Evidence.Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.Diabetes and the Association of Postoperative Hyperglycemia With Clinical and Economic Outcomes in Cardiac Surgery.Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check?Systematic review of guidelines on abdominal aortic aneurysm screening.Systematic review of guidelines on imaging of asymptomatic coronary artery disease.Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model.Lifestyle interventions in patients with coronary heart disease: a systematic review.Predictive value of updating Framingham risk scores with novel risk markers in the U.S. general population.Cardiovascular Risk Assessment: A Systematic Review of Guidelines.Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative.Impact of correlation of predictors on discrimination of risk models in development and external populations.Time-Limited Trials of Intensive Care for Critically Ill Patients With Cancer: How Long Is Long Enough?Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease.Reasons for admission and predictors of national 30-day readmission rates in patients with end-stage renal disease on peritoneal dialysis.Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population.Restriction of the referral of patients with stable angina for CT coronary angiography by clinical evaluation and calcium score: impact on clinical decision making.Assessing predictive performance beyond the Framingham risk score.National Estimates of 30-Day Unplanned Readmissions of Patients on Maintenance Hemodialysis.Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies.Do different methods of modeling statin treatment effectiveness influence the optimal decision?When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis.A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort.Performance of Framingham cardiovascular disease (CVD) predictions in the Rotterdam Study taking into account competing risks and disentangling CVD into coronary heart disease (CHD) and stroke.Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United StatesLifestyle advice and interventions for cardiovascular risk reduction: A systematic review of guidelinesComparative cost-effectiveness of non-invasive imaging tests in patients presenting with chronic stable chest pain with suspected coronary artery disease: a systematic reviewMaximizing society's overall health in the face of budgetary constraintsEarly Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United StatesNeoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level DataRisk-stratified versus Non-Risk-stratified Diagnostic Testing for Management of Suspected Acute Biliary Obstruction: Comparative Effectiveness, Costs, and the Role of MR CholangiopancreatographyWeb-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer
P50
Q24197484-EF257C7F-2337-409D-B82A-E16447321537Q28484624-2E54C400-792E-4BAD-8F3A-6D37B90E2ED5Q28652095-18CBE466-9AD6-4463-A684-E720D740FB20Q28652095-231B3C10-FD51-4D58-A321-037986C4EB16Q28659201-4A8B616C-6ED4-40C5-AA11-2B33B07BCB2FQ30235352-B6126A3B-BA4D-4C1C-AE4E-30AFFFDD43D9Q30251988-3F4C2964-B374-4099-AD0B-D2E1C9771EB6Q30277717-6A4153A8-9920-4B52-9377-A18881A4596DQ33523245-51E4BA58-91DE-4F73-8128-65A4B6530A2AQ33821679-62CCFE18-D1FA-4454-AB5A-004EB809AC5FQ33865423-AB10387A-5485-43F7-BDFC-28C8E2AAF561Q34502738-059246BE-576D-43F4-B8C5-A97AB0E3ADFBQ34835693-4C3C7E6D-4574-4527-9A65-73179CBD2A31Q35099546-F13F43ED-9F5E-40F2-9487-CFD9A39458DCQ36130030-758311A5-1511-4238-8577-28B2C5781921Q36326110-B5F2C31E-44D6-40AA-9EC0-3CCE3FBC02ACQ36350234-D7727F77-DC19-43C2-BB02-71A77C8BFD80Q36463609-1C02B8EF-7422-47BC-BA64-A1DF5C9F74B2Q38615440-058BE8DF-446C-40F7-8CC8-0138065AC101Q38934550-C5A8AFFE-FD64-4526-AF05-3C3FA8FA7E8BQ39286825-C2D38459-2B91-4A60-8127-BF63732FB5C0Q40065724-1113C9A7-4FCC-4394-A15E-39CBDD9EEC01Q40385193-1B70C4F8-5066-477A-9969-D97A324EDD46Q41141537-5ACC5315-EF6C-4A5D-9B15-6D898512B098Q43644876-E2FF87F9-1726-45D4-BF57-CB1EEE3A2D80Q44175819-66B5BA23-0B60-44EB-85A7-CA6F77600B69Q47751543-A934C5DC-358F-43D4-9F70-A91CDDC71209Q50023788-D0EB3A94-EFC5-4539-839E-FC0B7A3727BCQ51388742-57585FEA-ABBD-474F-B5DF-157D90FDF2EAQ51733174-4B74664A-4B84-40E1-960A-F1F863420E27Q53660419-15A8DE7F-2DE8-4DF3-B55F-B0E0951C913EQ54339935-0C0D828A-BF43-4F10-8C29-AFA48E4E7ABBQ57170982-787C6F45-F0B7-4C48-83DB-0048B5A1492BQ57743901-AA91D176-3E63-4404-9334-A18132B78442Q57744089-706721F4-D9BA-480A-9447-3125A864E129Q58563368-234B21F9-58BC-46DF-BCAD-83A69EC53F6EQ61808243-3950DC02-8C4E-4349-8185-264046BC27C1Q87892656-E389BD61-3A16-4F28-8C32-F82596BE37E5Q89026111-23DC9140-A835-4299-B20B-9FDC8987283DQ89546914-2D3C12E4-1C49-4AED-9442-BA6140FB8E93
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bart S Ferket
@ast
Bart S Ferket
@en
Bart S Ferket
@es
Bart S Ferket
@nl
Bart S Ferket
@sl
type
label
Bart S Ferket
@ast
Bart S Ferket
@en
Bart S Ferket
@es
Bart S Ferket
@nl
Bart S Ferket
@sl
altLabel
Bart Ferket
@en
prefLabel
Bart S Ferket
@ast
Bart S Ferket
@en
Bart S Ferket
@es
Bart S Ferket
@nl
Bart S Ferket
@sl
P106
P21
P31
P496
0000-0003-2754-545X